"AbbVie's Atogepant: Long-Term Safety and Efficacy for Migraine Prevention"
TL;DR
AbbVie Inc (NYSE: ABBV) released positive interim analysis results for its long-term study on atogepant, a drug for migraine prevention, leading to a 2.75% drop in its stock price. The study showed consistent improvements in monthly migraine days, headache days, and acute medication use days over 48 weeks, with no new safety concerns identified. AbbVie raised its long-term revenue outlook for atogepant and another drug, expecting peak combined revenues of more than $3 billion.
- What's Going On AbbVie Stock On Friday? Yahoo Finance
- Must-know guide to treating - and preventing - a migraine Daily Mail
- NICE recommends first oral treatment for chronic and episodic migraines Pavilion Health Today
- AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine PR Newswire
- AbbVie’s oral therapy Aquipta recommended by NICE for migraine prevention in adults PMLiVE
Want the full story? Read the original reporting
Read on Yahoo Finance